T lymphocytes modifying factors in sera of patients with Myasthenia gravis. 1983

G Skibiński, and B Ujma, and K Guzowski, and A Brzecki, and J Zwoliński, and Z Wieczorek

The examination of patients with Myasthenia gravis revealed that before thymectomy the number of T and B cells in the peripheral blood did not deviate from the norm. It was also observed that their sera contained factor stimulating T lymphocytes to the spontaneous rosette formation, theta antigen generation in xynogeneic system and hydrocortisone-resistant thymocytes. No factor inhibiting the spontaneous rosette formation by T lymphocytes or causing the transmission from Thy-1.2+ cells to Thy-1.2-cells was detected in these sera. Thymectomy resulted in the immediate fall of T lymphocytes number in the peripheral blood of the patients examined. Besides, serum of most patients almost totally lost the stimulating factor. The fall of T cells number did not involve the appearance of the inhibitory factor in the patients' serum. Different than in others results gave blood and serum analysis in the patient tymectomized 10 years earlier. Her blood contained the normal number of T and B lymphocytes and the stimulatory factor of a "limited" activity. It displayed only the ability of generating hydrocortisone-resistant cells, it appeared nonactive in generating theta antigen or restoring the ability of rosette formation by T cells.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D013934 Thymectomy Surgical removal of the thymus gland. (Dorland, 28th ed) Thymectomies
D013950 Thymus Gland A single, unpaired primary lymphoid organ situated in the MEDIASTINUM, extending superiorly into the neck to the lower edge of the THYROID GLAND and inferiorly to the fourth costal cartilage. It is necessary for normal development of immunologic function early in life. By puberty, it begins to involute and much of the tissue is replaced by fat. Thymus,Gland, Thymus,Glands, Thymus,Thymus Glands

Related Publications

G Skibiński, and B Ujma, and K Guzowski, and A Brzecki, and J Zwoliński, and Z Wieczorek
April 1979, Clinical and experimental immunology,
G Skibiński, and B Ujma, and K Guzowski, and A Brzecki, and J Zwoliński, and Z Wieczorek
March 1968, Life sciences,
G Skibiński, and B Ujma, and K Guzowski, and A Brzecki, and J Zwoliński, and Z Wieczorek
September 1979, Clinical and experimental immunology,
G Skibiński, and B Ujma, and K Guzowski, and A Brzecki, and J Zwoliński, and Z Wieczorek
February 1972, Igaku to seibutsugaku. Medicine and biology,
G Skibiński, and B Ujma, and K Guzowski, and A Brzecki, and J Zwoliński, and Z Wieczorek
July 1970, Clinical and experimental immunology,
G Skibiński, and B Ujma, and K Guzowski, and A Brzecki, and J Zwoliński, and Z Wieczorek
January 1996, Scandinavian journal of immunology,
G Skibiński, and B Ujma, and K Guzowski, and A Brzecki, and J Zwoliński, and Z Wieczorek
April 1999, Neurology,
G Skibiński, and B Ujma, and K Guzowski, and A Brzecki, and J Zwoliński, and Z Wieczorek
March 1982, JAMA,
G Skibiński, and B Ujma, and K Guzowski, and A Brzecki, and J Zwoliński, and Z Wieczorek
August 1991, Neurology,
G Skibiński, and B Ujma, and K Guzowski, and A Brzecki, and J Zwoliński, and Z Wieczorek
November 1992, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!